JP2011525523A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011525523A5 JP2011525523A5 JP2011515372A JP2011515372A JP2011525523A5 JP 2011525523 A5 JP2011525523 A5 JP 2011525523A5 JP 2011515372 A JP2011515372 A JP 2011515372A JP 2011515372 A JP2011515372 A JP 2011515372A JP 2011525523 A5 JP2011525523 A5 JP 2011525523A5
- Authority
- JP
- Japan
- Prior art keywords
- fviii
- buffer
- ligand
- resin
- multimodal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims 25
- 102100026735 Coagulation factor VIII Human genes 0.000 claims 19
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 claims 19
- 239000003446 ligand Substances 0.000 claims 9
- 239000011347 resin Substances 0.000 claims 7
- 229920005989 resin Polymers 0.000 claims 7
- 230000002779 inactivation Effects 0.000 claims 5
- 102000004169 proteins and genes Human genes 0.000 claims 5
- 108090000623 proteins and genes Proteins 0.000 claims 5
- 238000000746 purification Methods 0.000 claims 5
- 125000000129 anionic group Chemical group 0.000 claims 4
- 239000012539 chromatography resin Substances 0.000 claims 4
- 230000003993 interaction Effects 0.000 claims 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims 3
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims 3
- 239000000872 buffer Substances 0.000 claims 3
- 239000012928 buffer substance Substances 0.000 claims 3
- 150000001875 compounds Chemical class 0.000 claims 3
- 239000003599 detergent Substances 0.000 claims 3
- 239000012149 elution buffer Substances 0.000 claims 3
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 3
- 239000012528 membrane Substances 0.000 claims 3
- 150000002894 organic compounds Chemical class 0.000 claims 3
- 239000000126 substance Substances 0.000 claims 3
- 239000004475 Arginine Substances 0.000 claims 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 2
- 239000004472 Lysine Substances 0.000 claims 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 2
- 241000700605 Viruses Species 0.000 claims 2
- 239000007864 aqueous solution Substances 0.000 claims 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 2
- 238000011210 chromatographic step Methods 0.000 claims 2
- 150000002632 lipids Chemical class 0.000 claims 2
- 244000052769 pathogen Species 0.000 claims 2
- 230000001717 pathogenic effect Effects 0.000 claims 2
- 239000011534 wash buffer Substances 0.000 claims 2
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 claims 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 claims 1
- WOUANPHGFPAJCA-UHFFFAOYSA-N 2-[benzyl(methyl)amino]ethanol Chemical compound OCCN(C)CC1=CC=CC=C1 WOUANPHGFPAJCA-UHFFFAOYSA-N 0.000 claims 1
- OACIMSFRSUBGQU-UHFFFAOYSA-N 2-benzamidobutanoic acid Chemical compound CCC(C(O)=O)NC(=O)C1=CC=CC=C1 OACIMSFRSUBGQU-UHFFFAOYSA-N 0.000 claims 1
- VBAOEVKQBLGWTH-UHFFFAOYSA-N 2-pyridin-4-ylethanethiol Chemical compound SCCC1=CC=NC=C1 VBAOEVKQBLGWTH-UHFFFAOYSA-N 0.000 claims 1
- PWLKDZUOOBKOAW-UHFFFAOYSA-N 3-[3-methyl-5-(oxolan-2-ylmethylamino)anilino]benzoic acid Chemical compound C=1C(NC=2C=C(C=CC=2)C(O)=O)=CC(C)=CC=1NCC1CCCO1 PWLKDZUOOBKOAW-UHFFFAOYSA-N 0.000 claims 1
- 239000007995 HEPES buffer Substances 0.000 claims 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 239000007987 MES buffer Substances 0.000 claims 1
- 229920001213 Polysorbate 20 Polymers 0.000 claims 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims 1
- 239000013504 Triton X-100 Substances 0.000 claims 1
- 229920004890 Triton X-100 Polymers 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 238000001042 affinity chromatography Methods 0.000 claims 1
- 125000003158 alcohol group Chemical group 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 239000003957 anion exchange resin Substances 0.000 claims 1
- 238000010936 aqueous wash Methods 0.000 claims 1
- 239000007853 buffer solution Substances 0.000 claims 1
- 238000005341 cation exchange Methods 0.000 claims 1
- 239000003729 cation exchange resin Substances 0.000 claims 1
- 125000002091 cationic group Chemical group 0.000 claims 1
- 238000004587 chromatography analysis Methods 0.000 claims 1
- 239000000356 contaminant Substances 0.000 claims 1
- 238000010828 elution Methods 0.000 claims 1
- HQPMKSGTIOYHJT-UHFFFAOYSA-N ethane-1,2-diol;propane-1,2-diol Chemical compound OCCO.CC(O)CO HQPMKSGTIOYHJT-UHFFFAOYSA-N 0.000 claims 1
- 238000001914 filtration Methods 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 230000002209 hydrophobic effect Effects 0.000 claims 1
- 229910017053 inorganic salt Inorganic materials 0.000 claims 1
- 150000002500 ions Chemical class 0.000 claims 1
- 239000011159 matrix material Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 238000012433 multimodal chromatography Methods 0.000 claims 1
- 230000007935 neutral effect Effects 0.000 claims 1
- 125000004344 phenylpropyl group Chemical group 0.000 claims 1
- 230000001766 physiological effect Effects 0.000 claims 1
- 229920001993 poloxamer 188 Polymers 0.000 claims 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims 1
- 229920000053 polysorbate 80 Polymers 0.000 claims 1
- 239000011148 porous material Substances 0.000 claims 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims 1
- 239000012266 salt solution Substances 0.000 claims 1
- 238000001542 size-exclusion chromatography Methods 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 239000001632 sodium acetate Substances 0.000 claims 1
- 235000017281 sodium acetate Nutrition 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- STCOOQWBFONSKY-UHFFFAOYSA-N tributyl phosphate Chemical compound CCCCOP(=O)(OCCCC)OCCCC STCOOQWBFONSKY-UHFFFAOYSA-N 0.000 claims 1
- 238000005406 washing Methods 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12940208P | 2008-06-24 | 2008-06-24 | |
| US61/129,402 | 2008-06-24 | ||
| EP08158893 | 2008-06-24 | ||
| EP08158893.1 | 2008-06-24 | ||
| PCT/EP2009/057883 WO2009156430A1 (en) | 2008-06-24 | 2009-06-24 | A process of purifying coagulation factor viii |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011525523A JP2011525523A (ja) | 2011-09-22 |
| JP2011525523A5 true JP2011525523A5 (enExample) | 2012-08-09 |
| JP5619738B2 JP5619738B2 (ja) | 2014-11-05 |
Family
ID=40076764
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011515372A Active JP5619738B2 (ja) | 2008-06-24 | 2009-06-24 | 凝固第ｖｉｉｉ因子の精製方法 |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US8329871B2 (enExample) |
| EP (2) | EP2537862B1 (enExample) |
| JP (1) | JP5619738B2 (enExample) |
| KR (3) | KR20160104740A (enExample) |
| CN (1) | CN102066417B (enExample) |
| AU (1) | AU2009264282B2 (enExample) |
| BR (1) | BRPI0914695B1 (enExample) |
| CA (1) | CA2728047C (enExample) |
| DK (2) | DK2537862T3 (enExample) |
| ES (2) | ES2538706T3 (enExample) |
| IL (3) | IL209758A (enExample) |
| MX (1) | MX2010013908A (enExample) |
| PL (1) | PL2300497T3 (enExample) |
| PT (1) | PT2300497E (enExample) |
| RU (2) | RU2698392C2 (enExample) |
| SI (1) | SI2300497T1 (enExample) |
| UA (1) | UA100901C2 (enExample) |
| WO (1) | WO2009156430A1 (enExample) |
| ZA (1) | ZA201009162B (enExample) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009007451A1 (en) | 2007-07-11 | 2009-01-15 | Novo Nordisk A/S | Purification of factor viii using a mixed-mode or multimodal resin |
| EP2027875A1 (en) * | 2007-08-23 | 2009-02-25 | Octapharma AG | A Process for Isolation and Purification of a Target Protein free of Prion Protein (PrPSC) |
| MX2011001624A (es) | 2008-08-21 | 2011-03-28 | Octapharma Ag | Factor viii y ix humano producido en forma recombinante. |
| CA2735376C (en) * | 2008-09-03 | 2016-11-29 | Octapharma Ag | New protecting compositions for recombinantly produced factor viii |
| US20110166332A1 (en) * | 2008-09-12 | 2011-07-07 | Ge Healthcare Bio-Sciences Ab | Enhanced antibody aggregate removal with capto adhere in the presence of protein-excluded zwitterions |
| ES2596727T3 (es) * | 2010-03-30 | 2017-01-11 | Octapharma Ag | Procedimiento de purificación de un factor proteico de crecimiento G-CSF |
| ES2740825T3 (es) * | 2010-03-30 | 2020-02-06 | Octapharma Ag | Un procedimiento de purificación de proteínas dependientes de vitamina K |
| DK2561070T3 (en) | 2010-04-20 | 2015-08-17 | Octapharma Ag | NEW STABILIZER FOR PHARMACEUTICAL PROTEINS |
| WO2012049285A1 (en) | 2010-10-14 | 2012-04-19 | Octapharma Ag | A method for the quantitative glycosylation analysis of proteins |
| WO2012059495A1 (en) * | 2010-11-05 | 2012-05-10 | F. Hoffmann-La Roche Ag | Optimized method for antibody capturing by mixed mode chromatography |
| EP4353743A3 (en) * | 2011-05-13 | 2024-07-17 | Octapharma AG | A method of increasing the productivity of eucaryotic cells in the production of recombinant fviii |
| KR102001662B1 (ko) | 2011-06-17 | 2019-10-01 | 학교법인 히가시-니뽄-가쿠엔 | 루프스 안티코아귤란트 검출용 혈액 응고시간의 측정방법 |
| WO2013062841A1 (en) * | 2011-10-26 | 2013-05-02 | Bio-Rad Laboratories, Inc. | Removal of virucidal agents in mixed mode chromatography |
| CA2888824C (en) * | 2012-10-24 | 2021-02-02 | Genzyme Corporation | Elution of biomolecules from multi-modal resins using mes as mobile phase modifier |
| US20140154233A1 (en) * | 2012-12-05 | 2014-06-05 | Csl Limited | Method of purifying therapeutic proteins |
| US10188965B2 (en) | 2012-12-05 | 2019-01-29 | Csl Behring Gmbh | Hydrophobic charge induction chromatographic depletion of a protein from a solution |
| CN103880947B (zh) * | 2012-12-21 | 2016-01-13 | 武汉禾元生物科技股份有限公司 | 一种分离纯化高纯度重组人血清白蛋白的层析方法 |
| RU2768003C2 (ru) * | 2013-03-08 | 2022-03-22 | Джензим Корпорейшн | Интегрированное непрерывное производство терапевтических белковых лекарственных веществ |
| WO2014201400A2 (en) * | 2013-06-13 | 2014-12-18 | Biogen Idec Ma Inc. | Anti-factor viii antibodies or uses thereof |
| SG11201508835YA (en) | 2013-07-12 | 2015-11-27 | Merck Patent Gmbh | Removal of fragments from a sample containing a target protein using activated carbon |
| US10947269B2 (en) | 2013-08-08 | 2021-03-16 | Bioverativ Therapeutics Inc. | Purification of chimeric FVIII molecules |
| WO2015044836A1 (en) | 2013-09-24 | 2015-04-02 | Pfizer Inc. | Compositions comprising heterogeneous populations of recombinant human clotting factor xa proteins |
| TWI709569B (zh) | 2014-01-17 | 2020-11-11 | 美商健臻公司 | 無菌層析樹脂及其用於製造方法的用途 |
| TWI671312B (zh) * | 2014-01-17 | 2019-09-11 | 美商健臻公司 | 無菌層析法及製法 |
| AU2015207472B2 (en) * | 2014-01-20 | 2018-11-22 | Octapharma Ag | A process for manufacturing factor VIII having an improved ratio of FVIII:C/FVIII:Ag |
| ES2688066T3 (es) * | 2014-01-24 | 2018-10-30 | Am-Pharma B.V. | Procesamiento para recuperación y purificación de una fosfatasa alcalina |
| US20160347787A1 (en) | 2014-02-04 | 2016-12-01 | Biogen Ma Inc. | Use of cation-exchange chromatography in the flow-through mode to enrich post-translational modifications |
| CN104861060A (zh) * | 2014-02-21 | 2015-08-26 | 神州细胞工程有限公司 | 一种纯化凝血因子viii的方法 |
| KR20170010750A (ko) | 2014-05-29 | 2017-02-01 | 에이전시 포 사이언스, 테크놀로지 앤드 리서치 | 단백질 추출 방법들 |
| US10626164B2 (en) * | 2014-07-25 | 2020-04-21 | Csl Limited | Purification of VWF |
| GB201506117D0 (en) * | 2015-04-10 | 2015-05-27 | Ge Healthcare Bio Sciences Ab | Method for chromatography |
| GB201506113D0 (en) | 2015-04-10 | 2015-05-27 | Ge Healthcare Bio Sciences Ab | Method for chromatography |
| WO2016207328A1 (en) * | 2015-06-24 | 2016-12-29 | Glycotope Gmbh | PROCESS FOR THE PURIFICATION OF γ-CARBOXYLATED POLYPEPTIDES |
| EP3205665A1 (en) * | 2016-02-11 | 2017-08-16 | Octapharma AG | Method of separating factor viii from blood products |
| GB201617240D0 (en) * | 2016-10-11 | 2016-11-23 | Profactor Pharma Ltd | Purification process |
| CN111183151B (zh) * | 2017-06-23 | 2024-06-07 | 武田药品工业株式会社 | 因子viii亚种的纯化 |
| CN107226859B (zh) * | 2017-08-10 | 2020-11-24 | 博雅生物制药集团股份有限公司 | 一种人凝血因子ⅷ的制备方法 |
| US11584777B2 (en) | 2017-08-31 | 2023-02-21 | Green Cross Corporation | Method for purifying a sulfatase protein |
| ES2991988T3 (es) | 2017-10-30 | 2024-12-05 | Takeda Pharmaceuticals Co | Detergentes compatibles con el medio ambiente para la inactivación de virus con envoltura lipídica |
| AU2019332764B2 (en) | 2018-08-31 | 2025-05-29 | Genzyme Corporation | Sterile chromatography resin and use thereof in manufacturing processes |
| EP4093745A4 (en) * | 2020-01-20 | 2024-03-06 | Wuxi Biologics Ireland Limited | NEW WASH BUFFER SOLUTION FOR AFFINITY CHROMATOGRAPHY |
| CN118217951B (zh) * | 2024-04-01 | 2025-05-23 | 山东建筑大学 | 一种水中的高纯度磷回收装置和方法 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4540573A (en) | 1983-07-14 | 1985-09-10 | New York Blood Center, Inc. | Undenatured virus-free biologically active protein derivatives |
| US5605884A (en) | 1987-10-29 | 1997-02-25 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Factor VIII formulations in high ionic strength media |
| US5316680A (en) * | 1992-10-21 | 1994-05-31 | Cornell Research Foundation, Inc. | Multimodal chromatographic separation media and process for using same |
| DE69402716T2 (de) | 1993-06-11 | 1997-12-11 | Northern Telecom Ltd., Montreal, Quebec | Verfahren zur versorgung von durch den anwender gesteuerten anrufverwaltungsdiensten |
| DE4337573C1 (de) * | 1993-11-04 | 1995-05-18 | Octapharma Ag | Verfahren zur Herstellung einer virusinaktivierten Faktor VIII enthaltenden Fraktion mittels chromatographischer Methoden |
| SE9403915D0 (sv) | 1994-11-14 | 1994-11-14 | Annelie Almstedt | Process A |
| AUPR638801A0 (en) * | 2001-07-13 | 2001-08-09 | Life Therapeutics Limited | Factor viii separation |
| AU2005216847B2 (en) * | 2004-02-27 | 2010-04-01 | Cytiva Bioprocess R&D Ab | A process for the purification of antibodies |
| US9624260B2 (en) | 2004-06-07 | 2017-04-18 | Therapure Biopharma Inc. | Process for isolation of plasma or serum proteins |
| EP1707634A1 (en) | 2005-03-29 | 2006-10-04 | Octapharma AG | Method for isolation of recombinantly produced proteins |
| FR2887883B1 (fr) * | 2005-06-29 | 2007-08-31 | Lab Francais Du Fractionnement | Procede de separation des proteines fibrinogene, facteur xiii et colle biologique d'une fraction plasmatique solubilisee et de preparation de concentres lyophilises desdites proteines |
| EP1739179A1 (en) | 2005-06-30 | 2007-01-03 | Octapharma AG | Serum-free stable transfection and production of recombinant human proteins in human cell lines |
| BRPI0713252C1 (pt) * | 2006-07-14 | 2021-05-25 | Genentech Inc | processo para a recuperação de fator de crescimento endotelial vascular (vegf) recombinante reenovelado |
| RU2324495C1 (ru) * | 2006-08-31 | 2008-05-20 | Федеральное государственное унитарное предприятие "Научно-производственное объединение по медицинским иммунобиологическим препаратам "Микроген" Министерства здравоохранения Российской Федерации | Способ получения препарата фактора свертывания viii крови человека |
| WO2008092644A2 (en) * | 2007-02-01 | 2008-08-07 | Baxter International Inc. | Fviii-independent fix-mutant proteins for hemophilia a treatment |
| DK2167117T3 (da) * | 2007-06-13 | 2012-11-19 | Csl Behring Gmbh | Anvendelse af VWF-stabiliserede FVIII-præparater til ekstravaskulær administration til terapeutisk og profylaktisk behandling af blødningsforstyrrelser |
| WO2009007451A1 (en) * | 2007-07-11 | 2009-01-15 | Novo Nordisk A/S | Purification of factor viii using a mixed-mode or multimodal resin |
| GB0723712D0 (en) * | 2007-12-04 | 2008-01-16 | Apitope Technology Bristol Ltd | Peptides |
| DE102008032361A1 (de) * | 2008-07-10 | 2010-01-21 | Csl Behring Gmbh | Der Einsatz von Faktor VIII und vWF bzw. vWF-enthaltenden Konzentraten zur Therapie der durch Thrombocyten-Inhibitoren induzierte Koagulopathie |
-
2009
- 2009-06-24 CN CN200980123974.6A patent/CN102066417B/zh active Active
- 2009-06-24 WO PCT/EP2009/057883 patent/WO2009156430A1/en not_active Ceased
- 2009-06-24 JP JP2011515372A patent/JP5619738B2/ja active Active
- 2009-06-24 DK DK12179389.7T patent/DK2537862T3/en active
- 2009-06-24 AU AU2009264282A patent/AU2009264282B2/en active Active
- 2009-06-24 BR BRPI0914695-4A patent/BRPI0914695B1/pt active IP Right Grant
- 2009-06-24 PL PL09769279T patent/PL2300497T3/pl unknown
- 2009-06-24 KR KR1020167023450A patent/KR20160104740A/ko not_active Abandoned
- 2009-06-24 KR KR1020107028866A patent/KR101700722B1/ko active Active
- 2009-06-24 DK DK09769279.2T patent/DK2300497T3/da active
- 2009-06-24 MX MX2010013908A patent/MX2010013908A/es active IP Right Grant
- 2009-06-24 KR KR1020177024076A patent/KR101804136B1/ko active Active
- 2009-06-24 EP EP12179389.7A patent/EP2537862B1/en not_active Revoked
- 2009-06-24 RU RU2015141849A patent/RU2698392C2/ru active
- 2009-06-24 RU RU2011102437/10A patent/RU2567811C2/ru active
- 2009-06-24 ES ES12179389.7T patent/ES2538706T3/es active Active
- 2009-06-24 PT PT09769279T patent/PT2300497E/pt unknown
- 2009-06-24 CA CA2728047A patent/CA2728047C/en active Active
- 2009-06-24 UA UAA201100699A patent/UA100901C2/ru unknown
- 2009-06-24 EP EP09769279A patent/EP2300497B1/en active Active
- 2009-06-24 US US12/737,230 patent/US8329871B2/en active Active
- 2009-06-24 SI SI200930362T patent/SI2300497T1/sl unknown
- 2009-06-24 ES ES09769279T patent/ES2391613T3/es active Active
-
2010
- 2010-12-05 IL IL209758A patent/IL209758A/en active IP Right Grant
- 2010-12-05 IL IL229583A patent/IL229583B/en active IP Right Grant
- 2010-12-21 ZA ZA2010/09162A patent/ZA201009162B/en unknown
-
2013
- 2013-11-24 IL IL229583A patent/IL229583A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011525523A5 (enExample) | ||
| RU2011102437A (ru) | Способ очистки фактора свертывания крови viii | |
| CA2784278C (en) | Wash solution and method for affinity chromatography | |
| JP5323072B2 (ja) | 混合方式又は多様式樹脂を使用する第ｖｉｉｉ因子の精製 | |
| RU2012146084A (ru) | Способ очистки витамин-к-зависимых белков, таких как коагуляционный фактор ix | |
| CN1163600C (zh) | 人胰岛素原的制备方法 | |
| RU2015149979A (ru) | Способ очистки белка фактора роста | |
| JP2019034963A (ja) | 陽イオン交換基を用いた新規抗体精製法（Ｎｏｖｅｌ Ａｎｔｉｂｏｄｙ Ｐｕｒｉｆｉｃａｔｉｏｎ ｍｅｔｈｏｄ ｕｓｉｎｇ Ｃａｔｉｏｎ Ｅｘｃｈａｎｇｅｒ） | |
| JP2019528255A5 (enExample) | ||
| ES2552337T3 (es) | Procedimientos para la preparación de plasminógeno | |
| CN111172135A (zh) | 使用mes和mops作为流动相改性剂从多峰树脂洗脱生物分子 | |
| US20240025950A1 (en) | Method of purification of recombinantly-produced rsv proteins in trimeric form | |
| WO1995004077A1 (en) | Method of purifying plasminogen | |
| CN109803982A (zh) | Fviii的纯化过程 | |
| JP2017517514A (ja) | Ｈｍｇ−ｕｐ（超高純度グレードのヒト閉経期ゴナドトロピン）を得るための方法及び夾雑物を含まない組成物 | |
| EA040179B1 (ru) | Способ очистки fviii или его варианта с удаленным доменом b от клеточной культуры in vitro |